Announcement • May 16
Racura Oncology Receives Positive Safety Review Committee Recommendation for Ongoing Cpacs Clinical Trial Racura Oncology announced that the independent Safety Review Committee (SRC) has completed its review of safety data from Cohort 1 of the ongoing CPACS clinical trial, evaluating the safety and pharmacokinetics of RC220 alone and in combination with doxorubicin in advanced metastatic solid tumor patients. Following its review, the SRC recommended that the study continue, noting no safety concerns in patients treated with 40mg/m2 of RC220 as monotherapy, or 40mg/m2 of RC220 in combination with 60mg/m2 of doxorubicin, in the first patient cohort of this trial. Based on this positive SRC recommendation, Racura plans to proceed to screening of new eligible patients for enrolment in Cohort 2 (80mg/m2 RC220 dose level) using an updated trial protocol, which includes an initial lead-in safety monotherapy cycle of doxorubicin prior to the administration of RC220. This protocol update enables an assessment of the anthracycline-cardioprotective potential of RC220 using a blood-based molecular test. The Company has received the SRC's formal written recommendation and has promptly notified the clinical trial sites to initiate enrolment in Cohort 2, as patients present and meet the eligibility criteria. Recent Insider Transactions Derivative • May 09
CEO, MD & Director exercised options to buy AU$546k worth of stock. On the 7th of May, Daniel Tillett exercised options to buy 200k shares at a strike price of around AU$1.25, costing a total of AU$250k. This transaction amounted to 1.1% of their direct individual holding at the time of the trade. Since June 2025, Daniel's direct individual holding has increased from 17.27m shares to 18.82m. Company insiders have collectively bought AU$1.7m more than they sold, via options and on-market transactions, in the last 12 months. Announcement • May 08
Racura Oncology Reports Discovery of Primary Mechanism of Action for (E,E)-Bisantrene Racura Oncology, an Australian Phase 3 stage clinical biopharmaceutical company, reported the discovery of the primary mechanism of action (MOA) of its lead oncology asset, (E,E)-bisantrene. Bisantrene has a long clinical history of activity across a range of cancer indications, but its mechanism of action has been unknown. Preclinical studies undertaken by Racura and collaborators identified that (E,E)-bisantrene exerts its anticancer activity by binding to and stabilizing G-quadruplex (G4) DNA and RNA structures, key regulatory elements involved in controlling oncogene expression. At the American Association for Cancer Research (AACR) Annual Meeting 2026, Racura presented new preclinical data demonstrating that (E,E)-bisantrene directly binds and stabilizes G4 DNA structures within the c-MYC gene promoter region, resulting in potent suppression of c-MYC expression and broad cytotoxic activity in a wide range of cancer models. The MYC protein functions as a master regulator of gene expression, governing thousands of genes involved in cell growth, differentiation, survival, metabolic reprogramming, chemotherapy resistance, and immune surveillance. Crucially, MYC is the most commonly deregulated oncogene across human cancers, and has often been referred to as the 'holy grail' of targets due to its prevalence across many cancer indications. The promoter region of the c-MYC gene contains G4 DNA structures, which can suppress MYC expression when stabilized by drug binding. Racura is advancing a proprietary formulation of (E,E)-bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a Phase 3 clinical program in acute myeloid leukemia (AML), a Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin, where the company aims to deliver both cardioprotection and enhanced anticancer activity for solid tumor patients. Preclinical studies have highlighted how (E,E)-bisantrene silences c-MYC gene expression via G4-DNA binding and stabilization leading to clinically relevant and broad anticancer activity. 
